[Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer].

MLA

Gerson Cwilich, Raquel, et al. “[Clinicopathological Features, Prognosis and Influence in the Adjuvant Treatment of the Risk Recurrence Groups Determined by the 21 Gene Expression Profile, Oncotype Dx®, in Early Breast Cancer].” Gaceta Medica de Mexico, vol. 148, no. 2, Mar. 2012, pp. 117–24. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=22622310&authtype=sso&custid=ns315887.

APA

Gerson Cwilich, R., Alban de la Torre, L. F., Villalobos Prieto, A., & Serrano Olvera, J. A. (2012). [Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer]. Gaceta Medica de Mexico, 148(2), 117–124.

Chicago

Gerson Cwilich, Raquel, Luis Fernando Alban de la Torre, Alberto Villalobos Prieto, and Juan Alberto Serrano Olvera. 2012. “[Clinicopathological Features, Prognosis and Influence in the Adjuvant Treatment of the Risk Recurrence Groups Determined by the 21 Gene Expression Profile, Oncotype Dx®, in Early Breast Cancer].” Gaceta Medica de Mexico 148 (2): 117–24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=22622310&authtype=sso&custid=ns315887.